Geode Capital Management LLC Has $19.20 Million Position in Syndax Pharmaceuticals, Inc. $SNDX

Geode Capital Management LLC increased its stake in Syndax Pharmaceuticals by 1.3% in Q2, owning 2,049,350 shares valued at $19.20 million. Other institutional investors also adjusted their holdings. Syndax's CEO sold shares, and the company reported a Q3 revenue increase of 266.4% year-over-year. Analysts have given the stock a consensus rating of 'Moderate Buy' with a target price of $37.20.

Geode Capital Management LLC boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 1.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,049,350 shares of the company's stock after purchasing an additional 26,365 shares during the quarter. Geode Capital Management LLC owned about 2.38% of Syndax Pharmaceuticals worth $19,195,000 at the end of the most recent quarter.

Get Syndax Pharmaceuticals alerts:

Other institutional investors also recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Syndax Pharmaceuticals in the first quarter worth $179,000. XTX Topco Ltd bought a new position in Syndax Pharmaceuticals in the 1st quarter worth $783,000. Deutsche Bank AG lifted its position in Syndax Pharmaceuticals by 127.7% during the 1st quarter. Deutsche Bank AG now owns 204,732 shares of the company's stock worth $2,516,000 after acquiring an additional 114,828 shares during the last quarter. Invesco Ltd. boosted its holdings in Syndax Pharmaceuticals by 49.7% during the first quarter. Invesco Ltd. now owns 76,848 shares of the company's stock valued at $944,000 after acquiring an additional 25,524 shares during the period. Finally, Aigen Investment Management LP bought a new stake in Syndax Pharmaceuticals during the first quarter valued at about $297,000.

Insider Activity at Syndax Pharmaceuticals

In other news, CEO Michael A. Metzger sold 157,307 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the sale, the chief executive officer directly owned 298,661 shares in the company, valued at approximately $4,901,027.01. The trade was a 34.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.10% of the company's stock.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ:SNDX opened at $20.12 on Monday. The firm has a market capitalization of $1.75 billion, a PE ratio of -5.17 and a beta of 0.73. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06. Syndax Pharmaceuticals, Inc. has a 1-year low of $8.58 and a 1-year high of $20.20. The business's 50 day moving average is $15.85 and its 200-day moving average is $13.26.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its earnings results on Monday, November 3rd. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.04. Syndax Pharmaceuticals had a negative return on equity of 130.47% and a negative net margin of 428.48%.The firm had revenue of $45.87 million during the quarter, compared to analysts' expectations of $49.08 million. During the same period last year, the business earned ($0.98) earnings per share. Syndax Pharmaceuticals's quarterly revenue was up 266.4% compared to the same quarter last year. Sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on SNDX. Weiss Ratings reissued a "sell (d-)" rating on shares of Syndax Pharmaceuticals in a research report on Tuesday, November 25th. B. Riley raised Syndax Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, August 6th. Barclays increased their price objective on Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an "overweight" rating in a research report on Monday, November 24th. Citigroup raised their price objective on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Finally, The Goldman Sachs Group upped their target price on shares of Syndax Pharmaceuticals from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.20.

Read Our Latest Stock Report on SNDX

About Syndax Pharmaceuticals

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?

Before you consider Syndax Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.

While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here